# IFM2021-01 (NCT05572229)

> Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05572229
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: University Hospital, Lille
- Conditions: Multiple Myeloma
- Interventions: Teclistamab; Daratumumab; Lenalidomide
- Enrollment: 74
- Primary outcome: Rate of very good partial response (VGPR) or better according to the IMWG criteria in patients with newly diagnosed multiple myeloma after 4 cycles of treatment with Tec-Dara or Tec-Len

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 8
- X threads: 8
- Podcasts: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=ifm2021-01-nct05572229

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05572229", "email": "<work email>"}; the inbox owner confirms by the emailed link.